Form 4: ESSA Pharma Director Sells Shares in Acquisition

ESSA Pharma Inc. Director Richard Glickman disposed of 43,240 common shares as part of a business combination agreement where the company was acquired for cash and contingent value rights.

Summary

• Richard Glickman, a Director of ESSA Pharma Inc., reported the disposal of 43,240 common shares.
• The transaction occurred on October 9, 2025, as part of a Business Combination Agreement.
• Under the agreement, Xeno Acquisition Corp. acquired all outstanding common shares of ESSA Pharma Inc.
• Shareholders received approximately US$0.12 in cash per share.
• Shareholders also received one Contingent Value Right (CVR) per share, potentially worth up to US$0.14 per CVR, payable within specified periods.
• Following this transaction, Richard Glickman directly owns 0 common shares.

Sentiment

Score: 3

Explanation: The sentiment is low due to the very low cash consideration per share and the contingent nature of a significant portion of the potential payout, suggesting a less than ideal outcome for shareholders, despite providing an exit.

Positives

• The transaction provides immediate cash consideration of US$0.12 per share to shareholders.
• The inclusion of Contingent Value Rights (CVRs) offers potential additional upside of up to US$0.14 per CVR, allowing shareholders to benefit from future milestones or performance.
• The acquisition provides a clear exit strategy for existing shareholders.

Negatives

• Richard Glickman no longer holds any direct beneficial ownership in ESSA Pharma Inc. following the transaction.
• The CVRs introduce uncertainty regarding the final total value received, as their payout is contingent on future events.
• The cash consideration of US$0.12 per share is relatively low, suggesting a potentially distressed sale or a company with limited standalone value.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on future events, meaning shareholders may not receive the full US$0.14 per CVR.
• The specific periods for CVR payment are not detailed, introducing potential liquidity risk for the CVR holders.
• The acquisition price, including the potential CVR value, might not fully reflect the intrinsic value or future potential of ESSA Pharma Inc.

Future Outlook

The filing indicates the completion of an acquisition, suggesting ESSA Pharma Inc. will no longer operate as an independent publicly traded entity. The future value for former shareholders is tied to the performance and payout of the Contingent Value Rights.

Industry Context

This transaction represents a consolidation event within the biotechnology or pharmaceutical sector, where smaller companies are often acquired by larger entities for their assets, pipeline, or strategic fit. The use of CVRs is common in biotech acquisitions to bridge valuation gaps and share future development risks/rewards.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in biotech acquisitions is a common mechanism, similar to deals like the acquisition of Acceleron Pharma by Merck, where CVRs were used to provide additional value tied to specific clinical milestones.
• The per-share cash consideration of US$0.12, combined with a potential US$0.14 CVR, suggests a relatively low valuation for ESSA Pharma Inc. compared to some other biotech acquisitions which often involve significantly higher per-share premiums, especially for companies with promising late-stage assets. However, without specific details on ESSA's pipeline or market position, a direct comparison is challenging.
• The structure of the deal, involving a cash component and a contingent payment, aligns with typical industry practices for de-risking acquisitions in the pharmaceutical space.

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, marking an exit from their investment in ESSA Pharma Inc.
• Employees: The filing does not provide information on the impact on employees, but acquisitions often lead to organizational restructuring.
• Management: The reporting person, a director, no longer holds shares, indicating a change in their direct financial stake in the acquired entity.

Next Steps

• Payment of cash consideration to former ESSA Pharma Inc. shareholders.
• Potential future payments to CVR holders based on the achievement of specified milestones or conditions.

Key Dates

Recommendation

The company is being acquired, and the reporting person has disposed of all their shares. For existing shareholders, the transaction represents a forced sale at a specified price (cash + CVR). There is no longer an opportunity to hold shares in the independent entity. The recommendation is 'sell' in the context of the acquisition, as the shares are being converted into cash and CVRs. For new investors, there is no stock to buy.

Keywords

ESSA Pharma, EPIX, Form 4, Insider Transaction, Director Share Sale, Acquisition, Business Combination, Contingent Value Right, CVR, XenoTherapeutics, XOMA Royalty